Results 51 to 60 of about 164 (114)

Computational modeling approaches for circulating cellfree DNA in oncology

International audienceMany cancer patients undergoing immune-checkpoint inhibition (ICI) experience early progression (EP), defined as progression at the first imaging evaluation.
Nguyen Phuong, Linh
core   +3 more sources

Cell-Free DNA Fragmentomics: The New “Omics” on the Block [PDF]

Clinical Chemistry, 2020
Rossa W K Chiu, Ellen Heitzer, Y M Dennis Lo, Florent Mouliere, Dana W Y Tsui   +4 more
openaire   +1 more source

Cancer treatment monitoring using cell-free DNA fragmentomes

Nature Communications
AbstractCirculating cell-free DNA (cfDNA) assays for monitoring individuals with cancer typically rely on prior identification of tumor-specific mutations. Here, we develop a tumor-independent and mutation-independent approach (DELFI-tumor fraction, DELFI-TF) using low-coverage whole genome sequencing to determine the cfDNA tumor fraction and validate ...
Iris van ’t Erve, Bahar Alipanahi, Keith Lumbard, Zachary L. Skidmore, Lorenzo Rinaldi, Laurel K. Millberg, Jacob Carey, Bryan Chesnick, Stephen Cristiano, Carter Portwood, Tony Wu, Erica Peters, Karen Bolhuis, Cornelis J. A. Punt, Jennifer Tom, Peter B. Bach, Nicholas C. Dracopoli, Gerrit A. Meijer, Robert B. Scharpf, Victor E. Velculescu, Remond J. A. Fijneman, Alessandro Leal   +21 more
openaire   +3 more sources

Long cell-free DNA fragments predict early-progression in patients with advanced or metastatic cancer treated with immune-checkpoint inhibition.

International audienceBackground: Immune-checkpoint inhibition (ICI) has significantly advanced cancer treatment, but many patients experience early progression (EP).
Boutonnet, Audrey, Nguyen Phuong, Linh, Greillier, Laurent, Gaudy-Marqueste, Caroline, Salas, Sébastien, Garcia, Jean-Charles, Ginot, Frédéric, Deville, Jean-Laurent, Fina, Frédéric, Benzekry, Sébastien   +9 more
core   +1 more source

Analysis of cfDNA fragmentomics metrics and commercial targeted sequencing panels

Nature Communications
Abstract Fragmentomics based analysis of cell-free DNA (cfDNA) has recently emerged as a method to infer epigenetic and transcriptional data. Many of these reports analyze whole genome sequencing (WGS) which is not readily available clinically. Targeted exon panels are used for clinical cfDNA variant calling.
Kyle T. Helzer, Marina N. Sharifi, Jamie M. Sperger, Matthew R. Chrostek, Matthew L. Bootsma, Shannon R. Reese, Amy Taylor, Katie R. Kaufmann, Hannah Krause, Jennifer Schehr, Nan Sethakorn, David Kosoff, Christos E. Kyriakopoulos, Michael Bassetti, Grace Blitzer, John Floberg, Martin Sjöström, Andrew J. Armstrong, Himisha Beltran, Rana R. McKay, Felix Y. Feng, Ruth O’Regan, Kari B. Wisinski, Hamid Emamekhoo, Alex W. Wyatt, Joshua M. Lang, Shuang G. Zhao   +26 more
openaire   +3 more sources

Leveraging cfDNA fragmentomic features for the early detection of colorectal cancer

Frontiers in Immunology
Background Early detection of colorectal cancer (CRC) is crucial for improving patient outcomes. Cell-free DNA (cfDNA) analysis has emerged as a promising non-invasive approach for cancer detection. This study aims to develop a machine learning algorithm leveraging cfDNA fragmentomic features to accurately ...
Shan, Lina, Xu, Dengyong, Chen, Jie, Liu, Wenjia, Lin, Ji, Bao, Juhang, Huang, Jianfei, Zhang, Hanqing, Zhao, Hanchen, Xue, Wei, Lin, Ziao, Bai, Bingjun   +11 more
openaire   +2 more sources

Poster Sessions

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Genomic and fragmentomic landscapes of cell-free DNA for early cancer detection

Nature Reviews Cancer
Genomic analyses of cell-free DNA (cfDNA) in plasma are enabling noninvasive blood-based biomarker approaches to cancer detection and disease monitoring. Current approaches for identification of circulating tumour DNA typically use targeted tumour-specific mutations or methylation analyses.
Daniel C. Bruhm, Nicholas A. Vulpescu, Zachariah H. Foda, Jillian Phallen, Robert B. Scharpf, Victor E. Velculescu   +5 more
openaire   +3 more sources

Innovations in Early Lung Cancer Detection: Tracing the Evolution and Advancements in Screening

Lung cancer mortality rates, particularly non-small cell lung cancer (NSCLC), continue to present a significant global health challenge, and the adoption of lung cancer screening remains limited, often influenced by inequities in access to healthcare ...
Demetria Tennefoss, Lisa Carter-Bawa, Caitlin A. Schonewolf, Anil Vachani, Peter B. Bach, Chris Cisar, Ali H. Zaidi, Lindsey B. Cotton   +7 more
core   +1 more source

Abstracts

Cancer Science, Volume 116, Issue S1, Page 1-1975, January 2025.
wiley   +1 more source